XClose

UCL Queen Square Institute of Neurology

Home
Menu

Aligning Science Across Parkinson (ASAP) announces Global Parkinson’s Genetics Program (GP2)

6 December 2019

Global Parkinson’s Genetics Program (GP2) is ASAP's first resource, which will genotype 150,000 volunteers, led by NIH Distinguished Investigator Dr. Andrew Singleton, with steering committee members from UCL Queen Square Institute of Neurology.

The five year program will leverage existing consortia and cohorts to genotype more than 150,000 volunteers around the world — people with Parkinson’s disease or risk factors and control volunteers — to further understand the genetic architecture of this disease. Importantly, this program will integrate ancestrally diverse populations from around the world, addressing a large gap in our knowledge of PD. The underlying data, analytical processes, and results from GP2 will be made available to the research community as quickly as possible, with minimum barriers to access and use.

This program is the first resource project from ASAP, which has developed an ambitious roadmap to tackle key scientific challenges in Parkinson’s disease by supporting meaningful, multidisciplinary collaboration; generating research-enabling resources; and democratizing data. GP2 serves each ASAP goal and will be a valuable resource for the entire neurodegeneration community.

GP2 is a five-year study led by Andrew Singleton, PhD, of the National Institutes of Health and a steering committee which includes: Professor Huw Morris (Professor of Clinical Neurosciences, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology), Professor John Hardy ( Chair of Molecular Biology of Neurological Disease, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology) and Professor Nicholas Wood (Professor of Clinical Neurogenetics, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology)

"This initiative will analyse the genome in huge numbers of PD patients from around the globe. It seeks to not only improve our genetic knowledge of this common incurable disease, but also redress the current imbalance of genetic discoveries being focussed on principally Caucasian populations. This has the potential of equalising the gains of genetic discoveries in PD to the benefit or everyone."  Professor Nick Wood, Professor of Clinical Neurogenetics, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology

Further information

Source: Aligning Science Across Parkinson’s (ASAP)

 

Full steering committee:

  • Cornelis Blauwendraat, PhD
    National Institutes of Health, USA
  • Alexis Brice, MD
    Brain and Spine Institute, France
  • Ignacio Fernandez Mata, PhD
    Cleveland Clinic, USA
  • Brian Fiske, PhD
    Michael J. Fox Foundation, USA
  • Tatiana Foroud, PhD
    Indiana University, USA
  • Thomas Gasser, MD
    University of Tubingen, Germany
  • John Hardy, PhD
    University College London, United Kingdom
  • Peter Heutink, PhD
    German Center for Neurodegenerative Diseases, Germany
  • Christine Klein, MD
    University of Lubeck, Germany
  • Rejko Kruger, MD
    University of Luxembourg, Luxembourg
  • Ken Marek, MD
    Michael J. Fox Foundation, USA
  • Huw Morris, FCRP, PhD
    University College London, United Kingdom
  • Michael Nalls, PhD
    Data Tecnica International, USA
  • Alastair Noyce, MRCP, PhD
    Queen Mary University of London, United Kingdom
  • Alyssa Reimer, BA
    Michael J. Fox Foundation, USA
  • Ekemini A. U. Riley, PhD
    Milken Institute Center for Strategic Philanthropy, USA
  • Luba Smolensky, MS
    Michael J. Fox Foundation, USA
  • Enza Maria Valente, MD, PhD
    University of Pavia, Italy
  • Nigel Williams, PhD
    Cardiff University, United Kingdom
  • Nicholas Wood, MB ChB, PhD
    University College London, United Kingdom